Related Experiment Video
Updated: May 31, 2026
08:01
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Combination therapy for Alzheimer's disease.
Laxeshkumar Patel1, George T Grossberg
1Department of Neurology and Psychiatry, St. Louis University School of Medicine, St. Louis, Missouri 63104, USA. lpatel4@slu.edu
Drugs & Aging
|July 5, 2011
Summary
Combination therapy using memantine with cholinesterase inhibitors (ChEIs) is safe and well-tolerated for Alzheimer's disease (AD). This approach may be the current gold standard for treating moderate to severe AD and potentially mild to moderate AD.
Area of Science:
- Neuroscience
- Pharmacology
- Geriatrics
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Current AD treatments primarily offer symptomatic relief.
- Approved medications include cholinesterase inhibitors (ChEIs) and memantine.
Purpose of the Study:
- To review studies on the efficacy, safety, and tolerability of combination therapy for AD.
- To evaluate memantine combined with ChEIs (donepezil, galantamine, rivastigmine).
Main Methods:
- Systematic review of key studies.
- PubMed search for relevant literature.
- Focus on combination therapy of memantine and ChEIs.
Main Results:
- Combination therapy for AD appears safe and well-tolerated.
- Evidence suggests potential benefits for moderate to severe AD.
- May also be beneficial for mild to moderate AD.
Conclusions:
- Combination therapy represents a promising treatment strategy for AD.
- It may be considered the current gold standard for managing moderate to severe AD.
- Further research into combination therapy for mild to moderate AD is warranted.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...